Table 1

Baseline characteristics

Treatment group
ParameterMedical (n=213)Revascularisation (n=65)p Value
Age, years63 (53, 71)68 (59, 78)<0.01
Male74%80%0.30
Caucasian72%71%0.41
Hypertension67%79%0.08
Hyperlipidaemia70%69%0.91
Diabetes30%48%0.01
Peripheral vascular disease16%19%0.57
Prior myocardial infarction70%51%0.01
Prior percutaneous coronary intervention43%40%0.70
Prior coronary artery bypass grafting50%39%0.11
Prior revascularisation69%59%0.11
3-vessel disease54%57%0.63
Ejection fraction, %32 (26, 36)33 (28, 37)0.05
Prior smoking67%63%0.55
New York Heart Association class III–IV25%20%0.42
Charlson Index1 (0, 1)1 (0, 2)0.06
 134%38%0.18
 ≥223%31%
Body mass index, kg/m227 (25, 31)28 (26, 32)0.07
Heart rate, bpm73 (64, 85)69 (61, 78)0.04
Systolic blood pressure, mm Hg132 (117, 149)144 (127, 167)<0.01
β-Blocker52%51%0.85
ACE inhibitor62%66%0.60
Nitrate56%46%0.16
Statin25%44%<0.01
Aspirin68%56%0.07
Calcium channel blocker16%28%0.05
Diuretic17%28%0.07
  • Represented as median (Q1, Q3) or % unless otherwise indicated.